Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Closing the gap between basic and clinical research in AL and ATTR amyloidosis

Marina Ramirez-Alvarado • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Marina Ramirez-Alvarado, PhD, Mayo Clinic, Rochester, MN, comments on the importance of encouraging collaboration between different stakeholders in the field of amyloidosis to close the gap between basic and clinical research in AL and ATTR amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Honorarium from Attralus

More from Marina Ramirez-Alvarado

1:25
The importance of early diagnosis in systemic amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022
1:33
Rationale for anti-amyloid therapy in systemic amyloidosis
Marina Ramirez-Alvarado • 7 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals